CAS NO: | 1234490-83-5 |
包装: | 5mg |
市场价: | 2190元 |
Cas No. | 1234490-83-5 |
别名 | N-(2'-C-甲基-6-O-甲基-P-1-萘基-5'-鸟苷酰基)-L-丙氨酸2,2-二甲基丙酯,INX-08189 |
Canonical SMILES | COC1=C2N=CN([C@@H]3O[C@H](CO[P](=O)(N[C@@H](C)C(=O)OCC(C)(C)C)OC4=CC=CC5=C4C=CC=C5)[C@@H](O)[C@@]3(C)O)C2=NC(N)=N1 |
分子式 | C30H39N6O9P |
分子量 | 658.65 |
溶解度 | Soluble in DMSO |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Potent hepatitis C virus (HCV) replication inhibitor (EC50 = 35 nM). Is rapidly metabolized in primary human hepatocytes to 2'-C-methyl guanosine triphosphate, an inhibitor of HCV RNA-dependent RNA polymerase NS5b. Displays 10-fold reduction in potency in S282T mutant-expressing versus wild-type replicons. Exhibits synergy with Ribavirin . Orally bioavailable. Vernachio et al (2011) INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob.Agents Chemother. 55 1843 PMID:21357300 |McGuigan et al (2010) Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg.Med.Chem.Lett. 20 4850 PMID:20637609 |